Manganese is essential to all known living
organisms; it activates numerous enzyme systems including those
involved with glucose metabolism, energy production and superoxide
dismutase; it is a major constituent of several metalloenzymes,
hormones, and proteins of humans. Manganese is part of the
developmental process and the structure of the fragile ear bones and
joint cartilage. Excessive levels of Mn found in certain community
water supplies and in some industrial processes can produce a
Parkinsonian syndrome or a psychiatric disorder (locura manganica)
resembling schizophrenia.
Deficiency diseases of Mn are very striking ranging from severe birth
defects (Congenital ataxia, deafness, Chondrodystrophy), asthma,
convulsions, retarded growth, skeletal defects, disruption of fat
and carbohydrate metabolism to joint problems in children and adults
(TMJ, Repetitive Motion Syndrome, Carpal Tunnel Syndrome.
Repetitive Stress Injury or Repetitive Motion Syndrome now costs
corporate America $20 billion dollars per year and accounts for 56%
of the 331,600 gradual onset work related illnesses. In 1991
orthopedic surgeons performed 100,000 Carpal Tunnel operations (at
$4,000 per surgery) with a lost work, wages and medical cost of over
$29,000 per case.
Deficiency Diseases of Manganese
- Congenital ataxia
- Deafness (malformation of otolithes)
- Asthma
- Chondromalacia
- Chondrodystrophy
- "Slipped Tendon"
- Defects of chondroitin sulfate metabolism (poor cartilage
formation)
- TMJ
- Repetitive Motion Syndrome
- Carpal Tunnel Syndrome
- Convulsions
- Infertility (failure to ovulate; testicular atrophy)
- Still births or spontaneous abortions (miscarriages)
- Loss of libido in males and females
- Retarded growth rate
- Shortened long bones
At risk for The Repetitive Motion Syndromes are those working in the
fields of computers (journalism, airline reservations, directory
assistance, law, data entry, and graphic design and securities
brokerage. Chief among the blue-collar victims are the auto assembly
workers, chicken pluckers, meat cutters, postal employees, dock
workers, etc. Repetitive Motion Syndrome was observed three
centuries ago in monks who were scribes and was described in 1717 by
Bernardo Ramazzini, an Italian physician (considered the father of
occupational medicine).
Repetitive Motion Syndrome victims have reached such numbers that
federal legislation has been passed in the form of OSHA and
Americans with Disabilities Act (ADA) to ensure work place safety.
Large numbers of ergonomically correct keyboards and devices have
been developed, we see literally millions of people at work with
Velcro wrist, neck, elbow, finger, knee, back and hip supports - all
for manganese deficiencies!!! The allopathic medical profession
would still prefer to spend your money than to admit that the human
flesh needs Manganese.
Manganese is an essential trace mineral nutrient. Manganese is
needed for normal brain and muscle function, building bones, blood
clotting, cholesterol synthesis, fat synthesis, and DNA and RNA
synthesis. Manganese activates the enzyme responsible for the
formation of urea, the waste product of protein degradation. In
carbohydrate metabolism manganese is required for the synthesis of
glucose from non-carbohydrate substances (gluconeogenesis).
Manganese assists the action of superoxide dismutase, which degrades
superoxide, a free radical and a highly damaging form of oxygen. In
addition, manganese is required to synthesize components of
mucopolysaccharides (glycosaminoglycans), components of connective
tissue. A manganese-dependent enzyme of the brain synthesizes the
amino acid, glutamine, as a way of removing ammonia, a toxic product
of nitrogen metabolism. Conditions possibly associated with
manganese deficiency include osteoporosis, rheumatoid arthritis,
lupus erythrematosis, allergies, alcoholism and diabetes.
Requirements
The body contains low levels of manganese, and only minute
amounts are required each day to maintain this level. The manganese
concentration in tissues is stable primarily due to carefully
controlled excretion.
There is no Recommended Dietary Allowance for manganese. Instead
the Food and Nutrition Board has estimated a safe and adequate daily
intake as 2.0 to 5.0 mg for adults. Symptoms of manganese deficiency
in experimental animals include pancreatic pathology and
diabetes-like symptoms, impaired growth, reproductive abnormalities,
skeletal abnormalities, convulsions and ataxia (abnormal muscle
movements). Certain groups might be deficient in manganese: women,
especially those on weight loss diets; anyone on a
calorie-restricted diet; aged people; and vegetarians.
Safety
While manganese is relatively non-toxic, too much manganese
can interfere with the absorption of other minerals like iron. High
manganese intake can cause nerve damage, immune system malfunction,
and damage to pancreas, liver and kidney. Excessive calcium
supplements can interfere with manganese and iron uptake because
they all use the same entry mechanism into intestinal cells. (See
also allergy, immediate fat metabolism.)
Freeland-Graves, Jeanne, "Manganese: an Essential Nutrient for
Humans,"' Nutrition Today, (November-December 1988), pp.
13-19
Manganese - Biochemical Function
Manganese is both an activator, and a constituent of several
enzymes. Those activated by manganese are numerous and include
hydrolases, kinases, decarboxylases and transferases, but most of
these enzymes can also be activated by other metals, especially
magnesium. This does not apply, however, to the activation of
glycosyltransferases or possibly to that of xylosyltransferase.
Manganese metalloenzymes include arginase, pyruvate carboxylase,
glutamine synthetase, and manganese superoxide dismutase.
PHYSIOLOGICAL FUNCTIONS
A. Enzyme Activity
Like other essential trace elements, Mn can function both as
an enzyme activator and as a constituent of metalloenzymes.
Manganese-containing enzymes include arginase, pyruvate carboxylase,
and Mn-superoxide dismutase. While the number of Mn metalloenzymes
is limited, the enzymes that can be activated by Mn are numerous.
They include hydrolases, kinases, decarboxylases, and transferases (Groppel
and Anke, 1971). Whether an activator or a component of the enzyme
proper, Mn is often the priority cation, but another cation,
especially magnesium (Mg), can partially substitute for Mn with
little or no loss in enzymatic activity. Thus, biotin-dependent
enzymes such as pyruvate carboxylase continue to fix CO, during Mn
deficiency because Mg substitutes for Mn in the enzyme.
B. Bone Growth
In most species studied, Mn-deficient bones are considerably
shortened and thickened. Manganese is essential for development of
the organic matrix of the bone, which is composed, largely of
mucopolysaccharide. Impairment in mucopolysaccharide synthesis
associated with Mn deficiency has been related to the activation of
glycosyltransferases (Leach, 1971). These enzymes are important to
polysaccharide and glycoprotein synthesis, and Mn is usually the
most effective of the metal ions required.
While it would be tempting to suggest a relationship between
manganese and the pathogenesis of osteoporosis based on various
studies, more investigation and exposition are required in view of
the prevalence of the disease worldwide. Overt human manganese
deficiency has rarely been seen in man, but subliminal deficiency
symptoms may go unnoticed for years because most nutrient
deficiencies are not instantaneous, especially when looking at bone
health. Bone mass in adults changes slowly, and we can expect a
substantial lag between diet and its expression in skeletal mass.
C. Reproduction
Effects on reproduction were among the first signs of Mn
deficiency to be observed. The deficiency can cause an irreversible
congenital defect in young chicks, rats, and guinea pigs
characterized by ataxia and loss of equilibrium. Shils and McCollum
(1943) found several stages of Mn deficiency in female rodents: (1)
birth of viable young with ataxia; (2) nonviable young that die
shortly after birth; and (3) disturbance of estrus, with no
reproduction. Impaired or irregular estrus has also been observed in
cattle and swine. Hidiroglou (1975), on the basis of Mn tissue
-distribution studies of the reproductive tract of normal and
anestrus ewes, has suggested that Mn has a role in corpus luteum
functioning. In laying hens, Mn deficiency has resulted in a
decreased rate of egg production, poor shell quality, reduced
hatchability, and an embryonic deficiency called chondrodystrophy.
Testicular degeneration has been reported in Mn-deficient rats,
mice, and rabbits (Leach, 1978).
The essentiality of manganese has been demonstrated in numerous
species. The changes of manganese deficiency vary according to the
degree and duration of deficiency at different stages of the life
cycle. The main manifestations of manganese deficiency include a
high neonatal death rate, impaired growth, abnormal skeletal
development, congenital ataxia, disturbed or depressed reproductive
function, and defects in lipid and in carbohydrate metabolism. Many
of these gross manifestations of manganese deficiency are now
believed to be due to a defect in the synthesis of
mucopolysaccharides. Although available information on manganese
deficiency in man is limited, these findings suggest that manganese
may play a role as one potential factor in the development of
intrauterine malformations. Further research is needed to support
and clarify this suggestion.
D. Lipid Metabolism
A metabolic association between Mn and choline has been known
for some time. Fatty liver in rats induced by Mn deficiency is
alleviated by either Mn or choline. Also, Mn deficiency increases
fat deposition and backfat thickness in pigs. Both Mn and choline
are needed for prevention of perosis in poultry. Manganese is
involved in the biosynthesis of choline. Furthermore, the changes in
liver ultrastructure that arise in choline deficiency are very
similar to those in Mn deficiency (Bruni and Hegsted, 1970).
Deficiencies of Mn and choline both appear to affect membrane
integrity. Manganese also has a role in cholesterol biogenesis
(Davis et al., 1990).
We may postulate a number of ways in which manganese may play a role
in lipid and lipoprotein metabolism, which may be ultimately related
to the development of atherosclerosis.
Manganese may affect cell membrane fluidity and/or permeability
by its function as a cofactor for enzymes involved in cholesterol
and fatty acid biosynthesis. Changes in cholesterol and fatty acid
composition of cell membranes would in turn alter lipid:lipid
and lipid:protein ratios, which would ultimately affect
membrane fluidity/permeability. Furthermore, manganese, by being a
cofactor of MnSOD, protects membranes from free radical formation
and preserves the integrity of its lipid components. Glycoproteins
are integral components of the arterial extracellular matrix and
play an important role in maintaining structural integrity and
normal function of the arterial wall including regulating
permeability and retention of plasma components, controlling
vascular cell growth, and interacting with lipoproteins. Manganese,
as a specific activator of glycosyltransferases, may also affect
glycosylation of glycoproteins on cell membranes including
receptors. This would alter receptor composition and structural
properties and affect lipoprotein binding and their ultimate
metabolic fate.
Manganese may also affect lipoprotein composition and metabolism
by its role in stabilizing lipoprotein structure due to its high
affinity in complexing with the polar heads of lipoprotein
phospholipids and amino acid residues. Furthermore, manganese may
modify intramolecular interaction of the lipoprotein particle with
its receptor by bridging the anionic groups of cell membrane
glycosaminoglycans with certain amino acid residues and
phospholipids on the surface of the lipoprotein. Finally, manganese
may play a crucial role in the glycosylation of plasma
apolipoproteins in the liver Golgi apparatus by specifically
activating glycosyl transferases. Glycosylation as a prerequisite
for normal lipoprotein secretion has been speculated." Manganese
deficiency may result in abnormal lipoprotein formation and
impairment of lipoprotein secretion from the liver, thus
resulting in fatty liver formation observed in many studies.
Structural alteration of the lipoprotein particle may affect
apolipoprotein conformation and thus its recognition and eventual
catabolism by cell receptors.
This review clearly points to the need for more research with
animal models to unravel the mechanism(s) of manganese on lipid and
lipoprotein metabolism and with humans to determine the possible
role of dietary manganese in the development of atherosclerosis.
E. Carbohydrate Metabolism
Glucose utilization is impaired by Mn deficiency. Necropsy
has revealed gross abnormalities in the pancreas such as aplasia or
marked hypoplasia of all cellular components, so Mn may in some way
be involved in insulin formation or activity. Rats deficient in Mn
had fewer insulin receptors per cell compared to controls (Baly
et al., 1990). Biosynthesis of glycoproteins may be impaired in
Mn-deficient animals. Prothrombin is a glycoprotein whose synthesis
has long been known to be controlled by vitamin K. Manganese is also
required, and a Mn deficiency reduces the vitamin K-induced clotting
response (Doisey, 1974).
The intracellular concentration of manganese can be one regulator
of carbohydrate metabolism, and therefore fluctuations in its
concentration may provide a mechanism of cellular metabolic control.
Considerable evidence is accumulating that manganese has a critical
role in the regulation of both pancreatic exocrine and endocrine
function. Manganese deficiency in experimental animals results in a
diabetic-like glucose intolerance. This may result in part from
alterations in processes comprising glucose homeostasis including
pancreatic insulin synthesis, secretion and degradation, as well as
peripheral insulin action on target tissues. Interestingly,
diabetes itself may result in marked changes in manganese metabolism.
The functional significance of these changes is the subject of
debate. An excess of manganese can also affect insulin and
carbohydrate metabolism. These metabolic alterations may contribute
to the pathological consequences of manganese toxicity. While to
date there is only a single case report of a diabetic subject
responding in a positive manner to manganese supplements, the
elucidation of manganese's role in signal transduction pathways and
transcription processes will without question contribute to our
understanding of the pathogenesis and potential treatment of
diabetes and other disease states involving alterations in manganese
metabolism.
F. Cell Function and Structure
Abnormalities in cell function and ultrastructure,
particularly involving the mitochondria, occur in Mn deficiency
(Hurley and Keen, 1987). Manganese deficiency caused alterations in
cell membrane integrity in the liver, pancreas, kidney, and heart in
aged mice (Bell and Hurley, 1973).
G. Immune Function
Manganese plays a role in immunological function (Hurley and
Keen, 1987). Interaction of Mn with neutrophils and macrophages has
been demonstrated, possibly through interactions with the plasma
membrane of cells employed in the immune response (Rabinovitch and
Destefano, 1973).
H. Brain Function - Epilepsy
Manganese deficiency or toxicity can affect brain function
(Hurley, 1984). Manganese-deficient rats, whether they are ataxic or
not, are more susceptible to convulsions (Hurley et al.,
1963). Papavasiliou et al. (1979) reported that humans with
convulsive disorders, including epileptics, showed whole blood Mn
concentrations significantly below normal.
That a relationship exists between epilepsy and blood
manganese concentration has been repeatedly shown. While this
relationship seems to be independent of the anticonvulsant therapy
used in epilepsy, the seizures associated with the epilepsy
apparently cause an increase in the manganese concentrations in the
liver. However, the evidence that seizure frequency is responsible
for the decreased blood concentrations of epileptics is not as
strong. Increased susceptibility to seizures of animals exposed to
manganese deficiency in utero combined with the lack of
increased susceptibility to seizures when the exposure to manganese
deficiency begins postnatally indicates that congenital effects of
manganese deficiency are responsible for the increased seizure
susceptibility. The lower levels of manganese in the blood and brain
of the genetically epilepsy prone rat support a genetic relationship
between abnormal manganese metabolism and epilepsy. Glutamine
synthetase, the most obvious link between seizures and manganese,
has been compared between epileptic and normal animals, but at this
writing no differences have been found.
Other manganese dependent enzymes have been identified in the
brain, and some of these have also been associated with seizures.
While it is still possible that the lower blood manganese
concentrations found in epileptics are an epiphenomenon of seizure
activity, the evidence for a genetic relationship between the
occurrence of seizures and abnormal manganese metabolism is growing.
These two hypotheses proposed to explain the abnormalities in
manganese metabolism found in epileptics are not mutually exclusive,
and it is possible that both are true. The validity of the seizure
frequency hypothesis by no means excludes a genetic relationship
between epilepsy and abnormal manganese metabolism. At the same
time, the existence of a genetic relationship between manganese and
epilepsy does not exclude an effect of seizure frequency on blood
and tissue manganese concentrations. Since we are as yet unable to
assign cause and effect in this relationship with any assurance,
much work remains to be done to identify the biochemical basis for
the relationship.
I. Wound Healing
Wound healing in manganese-deficient rats was compared with
wound healing in control rats fed a complete diet. An acrylic
cylinder wound-healing model was used. Second generation deficient
male and female animals were used for the wound healing studies.
Deficient animals had lower growth rates, lower bone weights, and
typical bone changes. The dry weights of wound healing tissues were
significantly lower in the manganese-deficient animals. The total
glycosaminoglycan levels of the manganese -deficient and control
animals were not different as indicated by uronic acid content. The
chondroitin-4-sulfate level was decreased significantly in the wound
healing tissue of manganese-deficient rats, but the levels of
hyaluronic acid and dermatan sulfate were not significantly
different in the deficient and control groups. The incorporation of
1-14C-glucosamine into chondroitin-4-sulfate of the wound healing
tissue was significantly decreased in the manganese-deficient
animals. From these observations, it may be concluded that manganese
is required for the synthesis of chondroitin-4 -sulfate and that
manganese is required for normal wound healing.
Deficiency and Toxicity
Manganese deficiency has been produced in many species of
animals, but not, so far, in humans. Signs of manganese deficiency
include impaired growth, skeletal abnormalities, disturbed or
depressed reproductive function, ataxia of the newborn, and defects
in lipid and carbohydrate metabolism.
Unequivocal evidence of manganese deficiency in humans has not so
far been reported, but a possible case of such deficiency was
described by Doisy. A man fed a semipurified formula diet found to
be low in manganese (0.35 mg/day) lost weight and suffered depressed
growth of hair and nails, dermatitis and hypocholesterolemia, but
responded to being fed a mixed hospital diet; supplementation with
manganese alone was not tried.
Another possible case of manganese deficiency in humans was
reported by Friedman et al. Men fed a diet containing only 0. 11 mg
of manganese/day for 39 days exhibited decreased serum cholesterol
and a fleeting dermatitis (miliaria crystallina). Calcium,
phosphorus and alkaline phosphatase activity in blood increased.
However, because short-term manganese supplementation (10 days) did
not reverse these changes, the suggestion that the syndrome was
attributable to manganese deprivation was not substantiated.
Other possible signs of manganese deprivation have been reported.
A diabetic patient who was not responsive to insulin injections
responded to oral manganese with decreased blood glucose
concentrations. In addition, wholeblood manganese concentrations
have been reported to be low in patients with certain types of
epilepsy.
Manganese is often considered to be among the least toxic
of the trace elements when administered orally. Thus, reported cases
of human toxicity caused by oral ingestion of large amounts of
manganese are few. The most common form of manganese toxicity is the
result of chronic inhalation of large amounts of airborne manganese
in mines, steel mills and some chemical industries. The major signs
of manganese toxicity in animals are depressed growth, depressed
appetite, impaired iron metabolism and altered brain function. Signs
of toxicity in Chilean manganese miners were first manifested in the
form of severe psychiatric abnormalities, including
hyperirritability, violent acts and hallucinations; these changes
were called manganic madness. As the disease progressed, there was a
permanent crippling neurological disorder of the extrapyramidal
system with morphological lesions similar to those of Parkinson
disease.
Epidemiology of Deficiency and Toxicity
The natural incidence of effects attributable to abnormal
manganese nutrition is apparently exceedingly low. It has been
suggested that the high incidence of cartilage disorders in
children in some geographical areas may be the result of low intakes
of manganese.
POPULATIONS WITH SUBOPTIMAL STATUS
Another type of model to study manganese deficiency is the
use of human populations reported to have suboptimal status of the
mineral. This method may be practical, as gross deficiencies of
manganese have not been observed among free-living humans. A number
of disease states have been associated with poor manganese nutriture.
These include (patients with) epilepsy,' exocrine pancreatic
insufficiency, rheumatoid arthritis, hydralazine syndrome,"' Mseleni
joint disease, multiple sclerosis, senile cataracts, osteoporosis,
and those on chronic hemodialysis.
For example, two small studies in humans have been conducted that
suggest a link between manganese and osteoporosis. Strause and
Saltman reported that serum values of manganese in osteoporotic
patients were 25% of those of normal subjects. However, no
information was given as to the number of subjects or methods used,
and values reported for serum manganese in the control subjects
(0.04 mg/L or 40 mcg/L) are much higher than those reported by
others (1 mcg/L).
Yet evidence that a relationship exists is seen in a pilot study
by the author. Twenty-three osteoporotic and healthy postmenopausal
women matched for age were tested for the presence or absence of
osteoporosis by dual photon absorptiometry. Bone mineral density and
number of nontraumatic fractures in the osteoporotic and control
groups were 0.88 versus 1.29 g/Cm-sq. and 15 versus 0, p > 0.0001,
respectively. Plasma levels of manganese averaged 29% less in the
osteoporotic women, compared to the healthy controls. In addition,
the response of the plasma to an oral load of manganese was
significantly greater in the osteoporotic versus the control group,
as indicated by areas under the curve. These data suggest that
the osteoporotic women in this study had an impairment of manganese
absorption and/or status.
Another population that may have poor manganese nutriture is
epileptic patients. Tanaka observed that 1/3 of children in a
convulsive disorders clinic had lower blood manganese than
neurologically normal children. Treatment of one child having a
blood manganese level of 0.65 mcg/L with 20 mg Mn per day increased
the level to 1.2 mcg/L and paralleled a reduction in the number
of seizures. In 52 humans treated for epilepsy, Papavasiliou et
al. observed a relationship between low whole blood and hair levels
of manganese and high seizure activity. Patients with the lowest
levels of whole blood manganese had the greatest frequency of
seizures. In 44 epileptic patients treated for uncontrolled
seizures, Carl et al. found that mean whole blood levels of
manganese were lower than that of a normal population (0.84 versus
1. 19 mcg/L. But the most significant finding was that the
subjects who had epilepsy for unknown reasons had significantly
lower values of whole blood manganese (0.66 versus 0.94 mcg/L) than
those who had a history of trauma, which might have caused the
epilepsy.
In children, models of a manganese deficiency might be found in
those with inborn errors of metabolism associated with poor
manganese nutriture. These
include phenylketonuria (PKU), maple syrup urine disease,
galactosemia, and methylmalonic acidemia. Also, children with
Perthes' disease, a disorder in which there is abnormal growth with
disproportionately small lower arms and feet, have been found to
have lower levels of blood manganese.
As new parameters to assess manganese nutriture are developed,
the above populations might be utilized to test the responsiveness
of test parameters to alterations in manganese status. |